XHKG2616
Market cap387mUSD
Dec 23, Last price
2.36HKD
1D
2.61%
1Q
60.54%
IPO
-81.71%
Name
CStone Pharmaceuticals
Chart & Performance
P/E
—
P/S
6.10
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.12%
Rev. gr., 5y
105.85%
Revenues
464m
-3.64%
Net income
-367m
L-61.93%
CFO
-589m
L-3.86%
Earnings
Mar 25, 2025
Profile
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 463,842 -3.64% | 481,363 97.51% | 243,718 -76.54% | |||||
Cost of revenue | 935,411 | 1,207,623 | 1,884,769 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (471,569) | (726,260) | (1,641,051) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 61,929 | 67,347 | ||||||
Tax Rate | ||||||||
NOPAT | (471,569) | (788,189) | (1,708,398) | |||||
Net income | (367,234) -61.93% | (964,607) -51.47% | (1,987,447) 62.92% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 341,824 | 2,529 | 16,830 | |||||
BB yield | -12.03% | -0.05% | -0.17% | |||||
| Debt | ||||||||
Debt current | 139,313 | 44,918 | 43,948 | |||||
Long-term debt | 268,597 | 300,109 | 157,937 | |||||
Deferred revenue | 1,247 | 1,247 | ||||||
Other long-term liabilities | 130,696 | (218,986) | (115,811) | |||||
Net debt | (614,152) | (217,139) | (544,027) | |||||
| Cash flow | ||||||||
Cash from operating activities | (588,843) | (612,469) | (1,484,024) | |||||
CAPEX | (15) | (101,821) | (149,136) | |||||
Cash from investing activities | 619,605 | 365,119 | (826,552) | |||||
Cash from financing activities | 388,355 | 28,467 | 92,304 | |||||
FCF | (418,371) | (806,832) | (1,794,368) | |||||
| Balance | ||||||||
Cash | 1,048,521 | 1,042,091 | 1,726,339 | |||||
Long term investments | (26,459) | (479,925) | (980,427) | |||||
Excess cash | 998,870 | 538,098 | 733,726 | |||||
Stockholders' equity | (8,535,621) | (8,178,604) | (7,257,583) | |||||
Invested Capital | 9,486,595 | 8,690,662 | 8,499,937 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 1,263,073 | 1,172,839 | 1,165,209 | |||||
Price | 2.25 -51.40% | 4.63 -44.01% | 8.27 -18.44% | |||||
Market cap | 2,841,914 -47.67% | 5,430,245 -43.65% | 9,636,278 -9.15% | |||||
EV | 2,227,762 | 5,213,106 | 9,092,251 | |||||
EBITDA | (413,379) | (681,720) | (1,618,390) | |||||
EV/EBITDA | ||||||||
Interest | 11,819 | 8,477 | 2,242 | |||||
Interest/NOPBT | ||||||||